Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
47.84
-0.88 (-1.81%)
Feb 21, 2025, 4:00 PM EST - Market closed
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Tarsus Pharmaceuticals stock have an average target of 56, with a low estimate of 41 and a high estimate of 72. The average target predicts an increase of 17.06% from the current stock price of 47.84.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Feb 10, 2025 |
| Barclays | Barclays | Buy Maintains $60 → $62 | Buy | Maintains | $60 → $62 | +29.60% | Jan 27, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $65 → $72 | Buy | Maintains | $65 → $72 | +50.50% | Jan 22, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $36 → $41 | Hold | Maintains | $36 → $41 | -14.30% | Nov 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $63 → $65 | Buy | Maintains | $63 → $65 | +35.87% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
178.29M
from 17.45M
Increased by 921.89%
Revenue Next Year
331.31M
from 178.29M
Increased by 85.83%
EPS This Year
-3.28
from -4.62
EPS Next Year
-1.91
from -3.28
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 190.6M | 378.0M | 583.2M | |||
| Avg | 178.3M | 331.3M | 507.1M | |||
| Low | 167.6M | 287.1M | 408.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 992.2% | 112.0% | 76.0% | |||
| Avg | 921.9% | 85.8% | 53.1% | |||
| Low | 860.5% | 61.1% | 23.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -3.05 | -1.01 | 3.64 |
| Avg | -3.28 | -1.91 | 1.98 |
| Low | -3.36 | -3.25 | 0.75 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.